Back to Report Store Home

Blood Pressure Disorders Drug Development Pipeline Review, 2018

  • Published: Aug-2018
  • Report Code: GBIHC043IDB
  • Report Format: pdf

Description

List of Figures

Figure 1: Number of Products under Development for Hypertension

Figure 2: Number of Products under Development by Companies Hypertension

Figure 3: Number of Products under Development by Universities/Institutes Hypertension

Figure 4: Number of Products under Development for Hypotension

Figure 5: Number of Products under Development by Companies Hypotension

Figure 6: Number of Products under Development for Pulmonary Arterial Hypertension

Figure 7: Number of Products under Development by Companies Pulmonary Arterial Hypertension

Figure 8: Number of Products under Development by Universities/Institutes Pulmonary Arterial Hypertension

Figure 9: Number of Products by Top 10 Targets Hypertension

Figure 10: Number of Products by Stage and Top 10 Targets Hypertension

Figure 11: Number of Products by Top 10 Mechanism of Actions Hypertension

Figure 12: Number of Products by Stage and Top 10 Mechanism of Actions Hypertension

Figure 13: Number of Products by Top 10 Routes of Administration Hypertension

Figure 14: Number of Products by Stage and Top 10 Routes of Administration Hypertension

Figure 15: Number of Products by Top 10 Molecule Types Hypertension

Figure 16: Number of Products by Stage and Top 10 Molecule Types Hypertension

Figure 17: Number of Products by Targets Hypotension

Figure 18: Number of Products by Stage and Targets Hypotension

Figure 19: Number of Products by Mechanism of Actions Hypotension

Figure 20: Number of Products by Stage and Mechanism of Actions Hypotension

Figure 21: Number of Products by Routes of Administration Hypotension

Figure 22: Number of Products by Stage and Routes of Administration Hypotension

Figure 23: Number of Products by Molecule Types Hypotension

Figure 24: Number of Products by Stage and Molecule Types Hypotension

Figure 25: Number of Products by Top 10 Targets Pulmonary Arterial Hypertension

Figure 26: Number of Products by Stage and Top 10 Targets Pulmonary Arterial Hypertension

Figure 27: Number of Products by Top 10 Mechanism of Actions Pulmonary Arterial Hypertension

Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions Pulmonary Arterial Hypertension

Figure 29: Number of Products by Routes of Administration Pulmonary Arterial Hypertension

Figure 30: Number of Products by Stage and Routes of Administration Pulmonary Arterial Hypertension

Figure 31: Number of Products by Top 10 Molecule Types Pulmonary Arterial Hypertension

Figure 32: Number of Products by Stage and Top 10 Molecule Types Pulmonary Arterial Hypertension

License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$3995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$7990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$11985
Email to a colleague Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards